Log in

OrthoPediatrics Stock Forecast, Price & News

+0.23 (+0.52 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $44.60
50-Day Range
MA: $45.78
52-Week Range
Now: $44.60
Volume190,403 shs
Average Volume141,286 shs
Market Capitalization$871.89 million
P/E RatioN/A
Dividend YieldN/A
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, and QuickPack. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2007 and is headquartered in Warsaw, Indiana.
Read More
OrthoPediatrics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:KIDS



Sales & Book Value

Annual Sales$72.55 million
Book Value$8.51 per share


Net Income$-13,730,000.00


Market Cap$871.89 million
Next Earnings Date11/4/2020 (Confirmed)
OptionableNot Optionable
+0.23 (+0.52 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KIDS News and Ratings via Email

Sign-up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

OrthoPediatrics (NASDAQ:KIDS) Frequently Asked Questions

How has OrthoPediatrics' stock been impacted by Coronavirus (COVID-19)?

OrthoPediatrics' stock was trading at $39.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KIDS stock has increased by 12.2% and is now trading at $44.60.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of OrthoPediatrics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OrthoPediatrics

When is OrthoPediatrics' next earnings date?

OrthoPediatrics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for OrthoPediatrics

How can I listen to OrthoPediatrics' earnings call?

OrthoPediatrics will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) posted its earnings results on Wednesday, August, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.11. The firm earned $13.59 million during the quarter, compared to analyst estimates of $12.65 million. OrthoPediatrics had a negative return on equity of 13.25% and a negative net margin of 32.28%.
View OrthoPediatrics' earnings history

What price target have analysts set for KIDS?

6 analysts have issued twelve-month price targets for OrthoPediatrics' stock. Their forecasts range from $48.00 to $57.00. On average, they anticipate OrthoPediatrics' share price to reach $53.50 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts' price targets for OrthoPediatrics

Who are some of OrthoPediatrics' key competitors?

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), The Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

Who are OrthoPediatrics' key executives?

OrthoPediatrics' management team includes the following people:
  • Mr. Mark C. Throdahl, CEO & Director (Age 69, Pay $604.5k)
  • Mr. David R. Bailey, Pres (Age 41, Pay $444.36k)
  • Mr. Fred L. Hite, CFO, Principal Financial & Accounting Officer, COO and Director (Age 52, Pay $532.21k)
  • Mr. Daniel J. Gerritzen, VP of Legal & HR, Gen. Counsel and Sec. (Age 50, Pay $426k)
  • Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 50, Pay $444.91k)
  • Mr. Joel Batts, Sr. VP of Science & Technology
  • Dr. Peter F. Armstrong M.D., Chief Medical Officer & Chair of Surgeon Advisory Board (Age 73)
  • Mr. Joe Hauser, Sr. VP & GM of Trauma & Deformity Correction
  • Mr. Mark Karshner, Sr. VP of International Sales

When did OrthoPediatrics IPO?

(KIDS) raised $52 million in an initial public offering (IPO) on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

What is OrthoPediatrics' stock symbol?

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

Who are OrthoPediatrics' major shareholders?

OrthoPediatrics' stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (5.06%), CWM LLC (0.43%), Conestoga Capital Advisors LLC (0.15%), Envestnet Asset Management Inc. (0.12%), WINTON GROUP Ltd (0.07%) and Icon Wealth Partners LLC (0.03%). Company insiders that own OrthoPediatrics stock include Bernie B Berry III, David R Bailey, Gregory A Odle, Mark C Throdahl and Stephen F Burns.
View institutional ownership trends for OrthoPediatrics

Which major investors are selling OrthoPediatrics stock?

KIDS stock was sold by a variety of institutional investors in the last quarter, including CWM LLC. Company insiders that have sold OrthoPediatrics company stock in the last year include Bernie B Berry III, David R Bailey, Gregory A Odle, Mark C Throdahl, and Stephen F Burns.
View insider buying and selling activity for OrthoPediatrics

Which major investors are buying OrthoPediatrics stock?

KIDS stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, WINTON GROUP Ltd, Icon Wealth Partners LLC, Envestnet Asset Management Inc., BNP Paribas Arbitrage SA, HighMark Wealth Management LLC, and Conestoga Capital Advisors LLC.
View insider buying and selling activity for OrthoPediatrics

How do I buy shares of OrthoPediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OrthoPediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $44.60.

How big of a company is OrthoPediatrics?

OrthoPediatrics has a market capitalization of $871.89 million and generates $72.55 million in revenue each year. The company earns $-13,730,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. OrthoPediatrics employs 94 workers across the globe.

What is OrthoPediatrics' official website?

The official website for OrthoPediatrics is www.orthopediatrics.com.

How can I contact OrthoPediatrics?

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at 574-268-6379 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.